Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Ultra-Rare Products by Year
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M) ($M)
Amgen Ultra-Rare Products: $719M in FY2025, down 5.1% from a year earlier.
Where the FY2025 figure comes from
“|| Ultra-Rare products (1) | 685 | 34 | 719 | 758 | (5%)”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Product Sales Detail & Form 10-Q / 10-K Other Product Sales Footnote.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 719 | -5.1% | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 758 | +362.2% | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 164 | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Breakdown
What makes up ultra-Rare Products
- Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — U.S. product sales ($M)685 · FY2025
- Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Rest of World (ROW) product sales ($M)34 · FY2025
- Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide reported sales growth YoY (%)-5.0% · FY2025
- RAVICTI (glycerol phenylbutyrate — Urea Cycle Disorders) — U.S. sales ($M)337 · FY2025
- PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M)233 · FY2025
Cite this data
StockData. (2026). Amgen Ultra-Rare Products ($M), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-ultra-rare-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.